参考文献/References:
[1] Sahraian MA,Moghadasi AN,Azimi AR,et al.Diagnosis and management of neuromyelitis optica spectrum disorder(NMOSD)in iran:a consensus guideline and recommendations[J].Mult Scler Relat Disord,2017,18(11):144-151.
[2] Wingerchuk MD,banwell B,Bennett JL,et al.International panel for NMO diagnosis.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology,2015,85(2):177-189.
[3] Wingerchuk DM,Hogancamp WF,O`Brien PC,et al.The clinical course of neuromyelitis optica(Devise's syndrome)[J].Neurology,1999,53(5):1107-1114.
[4] Jarius S,Wildemann B.The History of neuromyelitis optica[J].J Neuroinflammation,2013,10:8.
[5] Wingerchuk DM,Lennon VA,Pittock SJ,et al.Revised diagnostic criteria for neuromyelitis optica[J].Neurology,2006,66:1485-1489.
[6] Lennon VA,Wingerchuk DM,Kryzer TJ,et al.A serum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis[J].Lancet,2004,364:2106-2112.
[7] Lennon VA,Kryzer TJ,Pittock SJ,et al.IgG marker of optic spinal multiple sclerosis binds to the aquaporin-4 water channel[J].J Exp Med,2005,202:473-477.
[8] Francesc G,Maarten JT,Josep D,et al.A clinical approach to diagnosis of autoimmune encephalitis[J].Lancet Neurol,2016,15(4):391-404.
[9] Bergamaschi R,Tonietti S,Franciotta D,et al.Oligoclonal bands in Devic`s neuromyelitis optica and multiple sclerosis:differences in repeated cerebrospinal fluid exa minations[J].Mult Scler,2004,10(1):2-4.
[10] Waters P,Reindl M,Saiz A,et al.Multicentre comparison of a diagnostic assay:aquaporin-4 antibodies in neuromyelitis optica[J].Neurol Neurosurg Psychiatry,2016,87(9):1005-1015.
[11] Cobo-Calvo A,Sepulveda M,Bernard-Valnet R,et al.Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis:Clinical and prognostic implications[J].Mult Scler,2016,22(3):312-319.
[12] 中国免疫学会神经免疫学分会,中华医学会神经病学分会神经免疫学组,中国医师协会神经内科分会神经免疫专业委员会.中国视神经脊髓炎谱系疾病诊断与治疗指南[J].中国神经免疫学和神经病学杂志,2016,23(3):155-166.
[13] 张 植,张 敏,刘恒方,等.MOG抗体阳性和AQP4抗体阳性NMOSD患者的临床及影像学分析[J].中风与神经疾病杂志,2018,35(10):873-876.
[14] Havla J,Kampfel T,Schinner R,et al.Myelin-oligodendrocyte-glycoprotein(MOG)autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration[J].Journal of Neurology,2017,264(1):139-151.
[15] 姜安琪.中枢神经系统炎性脱髓鞘病的诱发电位应用进展[J].中风与神经疾病杂志,2018,35(2):190-192.
[16] Klistorner A,Arvind H,Nguyen T,et al.Axonal loss and myelin in early ON loss in postacute optic neuritis[J].Ann Neurol,2008,64(3):325-331.
[17] Neto SP,Alvarenga RM,Vasconcelos CC,et al.Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica[J].Mult Scler,2013,19:173-178.
[18] Ohnari K,Okada K,Takahashi T,et al.Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder[J].Neurol Sci,2016,364:97-101.
[19] 张秀娟,高喜松.中性粒细胞淋巴细胞比值与急性特发性周围性面神经麻痹严重程度和恢复时间相关性研究[J].陕西医学杂志,2019,48(11):1529-1531.
[20] 任彩霞,余永平,冯丙东,等.抗NMDA受体脑炎42例临床分析[J].陕西医学杂志,2016,45(9):1145-1146.
[21] Cree BA,Lamb S,Morgan K,et al.An open label study of the effects of rituximab in neuromyelitis optica [J].Neurology,2005,64(7):1270-1272.
[22] Cai T,Wang B,Wu J.Progress of specific targeting immunotherapy in neuromyelitis optica spectrum disorder[J].Chin J Clin Neurosci 2018,26(3):314-319,355.
[23] Lindsey JW,Meulmester KM,Bord SA,et al.Variable results after rituximab in neuromyelitis optica[J].J Neurol Sci,2012,317(1-2):103-105.
[24] Yang CS,Yang L,Li T,et al.Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica [J].Neurology,2013,81(8):710-713.
[25] Dai YQ,Lu TT,Wang YG,et al.Rapid exacerbation of neuromyelitis optica after rituximab treatment[J].J Clin Neurosci,2016,26:168-170.
[26] 方丽波,刘广志,薛迎红.视神经脊髓炎谱系疾病的免疫治疗策略[J].中国康复理论与实践,2018,24(8):987-992.
[27] Kim SH,Huh SY,Lee SJ,et al.A 5-year follow-up of rituximIgG treatment in patients with neuromyelitis optica spectrum disorder[J].JAMA Neurology,2013,70(9):1110-1117.
[28] Duddy M,Niino M,Adatia F,et al.Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis[J].Journal of Immunology,2007,178(10):6092-6099.
[29] Kim SH,Kim W,Li XF,et al.Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing Neuromyelitis optica over 2 years [J].Archives of Neurology,2011,68(11):1412-1420.